HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

MEDP

Medpace Holdings, Inc. (NASDAQ)

Healthcare — Diagnostics & Research

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Hold 2.6 / 5 12 analysts
$528.12
$-3.55 (-0.67%)
Target: $443.50 (-16.0%)
Sign in to add MEDP to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$15.52B
P/E Ratio (TTM)34.25
Forward P/E28.97
EPS (TTM)$15.87
Dividend Yield-
Profit Margin17.19%
Revenue Growth26.50%
ROE77.25%
Debt/Equity24.42
Recommendation Hold 2.6
Analyst Target$443.50
Analysts12
Indexes NASDAQ

Technical Indicators

RSI (14)79.2
Beta1.18
SMA 20-
SMA 40-
52-Week High$628.92
52-Week Low$306.70
50-Day Avg$450.90
200-Day Avg$513.48
Avg Volume359.7K
Volume479.2K

Performance Analysis

NEUTRAL

MEDP presents a mixed picture with both positive and negative indicators.

~ Trading at 69% of its 52-week range.
- RSI at 79.2 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ Strong revenue growth of 26.5% year-over-year.
~ Wall Street consensus is "Hold" from 12 analysts.
- Average analyst target of $443.50 implies 16.0% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:19 UTC

Back to Screener Export Report